CancerWallonia (@CancerWallonia) profile picture

CancerWallonia

@CancerWallonia

Cancer: from Wallonia to the World, from the World to Wallonia - Cancer: la Wallonie parle au Monde, le Monde parle à la Wallonie

 Wallonia (Wallonie), Belgium
Joined October 2014
  • Tweets82.7K
  • Following182
  • Followers870
629Media
Photo by CancerWallonia (@CancerWallonia)Photo by CancerWallonia (@CancerWallonia)Photo by CancerWallonia (@CancerWallonia)Photo by CancerWallonia (@CancerWallonia)Photo by CancerWallonia (@CancerWallonia)Photo by CancerWallonia (@CancerWallonia)Photo by CancerWallonia (@CancerWallonia)Photo by CancerWallonia (@CancerWallonia)Photo by CancerWallonia (@CancerWallonia)Photo by CancerWallonia (@CancerWallonia)
#FDA approves #amivantamab and #hyaluronidase-lpuj (#Rybrevant #Faspro) for subcutaneous injection. #CancerWallonia Marc #Lacroix
73
#FDA grants regular approval to #rucaparib (#Rubraca) for metastatic castration-resistant #prostate #cancer #CancerWallonia Marc #Lacroix
32
#FDA approves fam-#trastuzumab #deruxtecan-nxki with #pertuzumab for unresectable or metastatic #HER2-positive #breast #cancer #CancerWallonia Marc #Lacroix
26
#FDA approves #niraparib and #abiraterone acetate (#Akeega) plus #prednisone for #BRCA2-mutated #metastatic castration-sensitive #prostate #cancer #CancerWallonia Marc #Lacroix
54
#FDA approves #lisocabtagene #maraleucel (#breyanzi) for relapsed or refractory marginal zone lymphoma (#MZL) #CancerWallonia Marc #Lacroix
25
#FDA grants traditional approval to #pirtobrutinib (#Jaypirca) for chronic lymphocytic leukemia (#CLL) and small lymphocytic lymphoma (#SLL) #CancerWallonia Marc #Lacroix
20
#FDA approves #durvalumab (#Imfinzi) for resectable #gastric or #gastroesophageal #junction #adenocarcinoma #CancerWallonia Marc #Lacroix
17
#FDA approves #pembrolizumab (#Keytruda) with enfortumab vedotin-ejfv (#Padcev) for muscle invasive #bladder #cancer #CancerWallonia Marc #Lacroix
27
#FDA grants traditional #approval to #tarlatamab-dlle (#Imdelltra) for extensive stage small cell lung cancer (#SCLC). fda.gov/drugs/resources-info…. Followed by Marc #Lacroix, #CancerWallonia
FDA grants traditional approval to tarlatamab-dlle for extensive stage

FDA grants traditional approval to tarlatamab-dlle for extensive stage

On November 19, 2025, the Food and Drug Administration granted traditional approval to tarlatamab-dlle (Imdelltra, Amgen Inc.) for adults with extensive stage s

fda.gov
73
#FDA grants accelerated #approval to #sevabertinib (#Hyrnuo) for non-squamous non-small cell #lung #cancer (#NSCLC). fda.gov/drugs/resources-info…. Followed by Marc #Lacroix, #CancerWallonia
FDA grants accelerated approval to sevabertinib

FDA grants accelerated approval to sevabertinib

On November 19, 2025, the Food and Drug Administration granted accelerated approval to sevabertinib.

fda.gov
50
#FDA grants traditional #approval to #daratumumab and #hyaluronidase-fihj (#Darzalex #FasPro) for newly diagnosed light chain #amyloidosis. fda.gov/drugs/resources-info…. Followed by Marc #Lacroix, #CancerWallonia
FDA grants traditional approval to daratumumab and hyaluronidase-fihj

FDA grants traditional approval to daratumumab and hyaluronidase-fihj

On November 19, 2025, the Food and Drug Administration granted traditional approval to daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech Inc.

fda.gov
52
#FDA approves #selumetinib (###koselugo) for adults with #neurofibromatosis type 1 (#NF1) with symptomatic, inoperable #plexiform #neurofibromas. fda.gov/drugs/resources-info…. Followed by Marc #Lacroix, #CancerWallonia
FDA approves selumetinib for adults with neurofibromatosis type 1 with

FDA approves selumetinib for adults with neurofibromatosis type 1 with

On November 19, 2025, the Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca Pharmaceuticals LP) for adults with neurofibromatosis type 1

fda.gov
75
#FDA approves #epcoritamab-bysp (#Epkinly) for #follicular #lymphoma indications. fda.gov/drugs/resources-info… Followed by Marc #Lacroix, #CancerWallonia
FDA approves epcoritamab-bysp for follicular lymphoma indications

FDA approves epcoritamab-bysp for follicular lymphoma indications

FDA approves epcoritamab-bysp for follicular lymphoma indications

fda.gov
69
#FDA approves #ziftomenib (#Komzifti) for #relapsed or #refractory acute myeloid #leukemia (#AML) with a #NPM1 mutation fda.gov/drugs/resources-info… Followed by Marc #Lacroix, #CancerWallonia
FDA approves ziftomenib for relapsed or refractory acute myeloid leuke

FDA approves ziftomenib for relapsed or refractory acute myeloid leuke

On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.).

fda.gov
28
#FDA approves #daratumumab (#Darzalex) and #hyaluronidase-fihj for high-risk smoldering #multiple #myeloma (followed by Marc #Lacroix, #CancerWallonia)
59
#Cancer drug approval up to November 2025: #Datopotamab deruxtecan, #Mirdametinib, #Vimseltinib, #Penpulimab, #Avutometinib, #Defactinib, #Telisotuzumab vedotin, ##Taletrectinib, #Linvoseltamab, #Sunvozertinib, #Dordaviprone, #Zongertinib, #Imlunestrant .
226
FDA approves #revumenib for #relapsed or #refractory acute myeloid #leukemia (#AML) with a susceptible #NPM1 mutation (followed by Marc #Lacroix, #Wallonia).
55
#wordcloud @wordnuvola
22
#FDA approves #belantamab #mafodotin-blmf for #relapsed or #refractory multiple #myeloma (followed by Marc #Lacroix (#CancerWallonia)
51
E, E-M5479, E-P147, E-P177, E-M215, E-M35, E-Z827, E-L19, E-M81, E-PF2548, E-Y8827, E-PF2546, E-Z5009, E-MZ141, E-BY9777 = E-MZ151 (yfull.com/tree/E-BY9777/ , April 2022)
1
1
Load more